|
Market Closed -
OTC Markets
15:59:59 2026-10-01 EDT
|
5-day change | 1st Jan Change | ||
| 14.44 USD | -0.21% |
|
-2.96% | +8.65% |
Business description: Astellas Pharma Inc.
Number of employees: 14,099
Sales by Activity: Astellas Pharma Inc.
| Fiscal Period: March | 2022 (JPY) | 2023 (JPY) | 2024 (JPY) | 2025 (JPY) | 2026 (JPY) |
|---|---|---|---|---|---|
Pharmaceutical | 1,296B | 1,519B | 1,604B | 1,912B | 2,139B |
Geographical breakdown of sales: Astellas Pharma Inc.
| Fiscal Period: March | 2022 (JPY) | 2023 (JPY) | 2024 (JPY) | 2025 (JPY) | 2026 (JPY) |
|---|---|---|---|---|---|
USA | 544B | 658B | 669B | 872B | 946B |
Others | 483B | 576B | 649B | 760B | 876B |
Japan | 269B | 285B | 286B | 280B | 317B |
Executive Committee: Astellas Pharma Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 64 | 2023-02-09 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 55 | 2023-10-31 |
Tatjana Dragovic
CMP | Compliance Officer | - | 2025-03-31 |
| Chief Tech/Sci/R&D Officer | - | - | |
| Compliance Officer | 59 | 2022-09-30 |
Composition of the Board of Directors: Astellas Pharma Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Kenji Yasukawa
CHM | Chairman | 66 | 2023-02-09 |
Naoki Okamura
BRD | Director/Board Member | 64 | 2019-05-31 |
| Director/Board Member | 59 | 2023-05-31 | |
| Director/Board Member | 72 | 2023-05-31 | |
Yoichi Ohno
BRD | Director/Board Member | 65 | 2023-05-31 |
Rie Akiyama
BRD | Director/Board Member | 56 | 2023-05-31 |
Tomoko Aramaki
BRD | Director/Board Member | 57 | 2024-05-31 |
Rika Hirota
BRD | Director/Board Member | 59 | 2024-05-31 |
Mark Enyedy
BRD | Director/Board Member | 61 | 2025-06-18 |
Shigeki Takahara
BRD | Director/Board Member | 67 | 2026-06-18 |
Holdings: Astellas Pharma Inc.
| Name | Stocks | % | Valuation |
|---|---|---|---|
ONCOLYS BIOPHARMA INC. 2.47% | 727,200 | 2.47% | 21 M $ |
ASTELLAS PHARMA INC. 0.03% | 471,800 | 0.03% | 7 M $ |
KYNTRA BIO, INC. 4.91% | 198,734 | 4.91% | 2 M $ |
Company details: Astellas Pharma Inc.
Group companies: Astellas Pharma Inc.
| Name | Category and Sector |
|---|---|
Astellas BV
 Astellas BV Financial ConglomeratesFinance Functions as an investment holding company |
Financial Conglomerates
|
Other Pharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.62% | -0.10% | +50.70% | +114.07% | 1,031B | |
| -2.30% | -3.90% | +39.50% | +66.07% | 638B | |
| -0.63% | -1.94% | +12.26% | +74.38% | 462B | |
| -1.03% | -2.88% | +71.35% | +39.69% | 359B | |
| -0.03% | -3.91% | +34.28% | +39.35% | 335B | |
| -1.58% | +0.39% | +17.92% | +25.77% | 273B | |
| -2.02% | -3.20% | +7.60% | +8.38% | 253B | |
| -3.38% | +0.29% | +44.32% | +51.54% | 228B | |
| -1.04% | -2.56% | +32.88% | +96.82% | 185B | |
| Average | -1.33% | -0.36% | +34.53% | +57.34% | 418.21B | |
| Weighted average by Cap. | -1.12% | -0.35% | +38.05% | +69.18% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4503 Stock
- ALPMY Stock
- Company Astellas Pharma Inc.
Select your edition
All financial news and data tailored to specific country editions
